• If you are wondering whether Abbott Laboratories is attractively priced or just a value trap, the stock’s recent performance and current valuation metrics provide some clear signals to consider.
• The share price recently closed at US$87.83, with returns roughly flat over the last 30 days, up 0.5%, but down 29.3% year to date and down 32.7% over the past year.
• Recent coverage of Abbott Laboratories has focused on how the stock’s weaker one year and multi year returns, down 32.7% over one year and 16.6% over five years, contrast with its reputation as a large healthcare company. This context has prompted fresh interest in whether the current price better reflects shorter term sentiment shifts or a more fundamental change in expectations.
• On Simply Wall St’s valuation checks, Abbott Laboratories scores a full 6 out of 6 for being assessed as undervalued. The next sections will compare different valuation approaches and then conclude with a way to place those numbers within a broader narrative that investors can use.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Abbott Laboratories might be worth by projecting its future cash flows and then discounting those back to today using an appropriate rate. It is essentially asking what all those future dollars are worth in today’s terms.

For Abbott Laboratories, the latest twelve month free cash flow (FCF) is reported at about $7.1b. Using a 2 Stage Free Cash Flow to Equity model, analysts provide explicit FCF estimates out to 2028, with Simply Wall St extrapolating further to build a 10 year path. Within that projection, FCF for 2028 is $10.4b, and discounted values are supplied for each year through 2035, reflecting how cash further out is worth less today.

Pulling those cash flows together, the model arrives at an estimated intrinsic value of $139.69 per share. Compared with the recent share price of $87.83, this indicates that, under these assumptions, Abbott Laboratories is trading at a 37.1% discount to that DCF estimate.

Result: UNDERVALUED (based on this DCF model’s assumptions)

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 37.1%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings (P/E)

For profitable companies like Abbott Laboratories, the P/E ratio is a useful yardstick because it links what you pay for the stock to the earnings the business is currently generating. In simple terms, a higher P/E usually reflects higher growth expectations or lower perceived risk, while a lower P/E can reflect lower expected growth or higher risk.

Abbott Laboratories currently trades on a P/E of 24.47x. This is close to the broader Medical Equipment industry average P/E of 24.62x and below the peer group average of 30.63x. Simply Wall St also calculates a proprietary “Fair Ratio” of 30.10x for Abbott Laboratories. This is an estimate of what the P/E might be, given factors such as the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio is more tailored than simple industry or peer comparisons because it adjusts for Abbott Laboratories specific fundamentals rather than treating all companies in the sector as identical. Comparing the current P/E of 24.47x with the Fair Ratio of 30.10x indicates that the stock is trading below that customised benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St take the story you believe about Abbott Laboratories, such as whether the company’s cancer diagnostics expansion and dividend history will support future repricing or whether utilization, inflation and competition will keep pressure on earnings, and connect that story to a set of explicit forecasts for revenue, earnings, margins and a fair value. They then compare that fair value to the current price so you can judge if the stock looks attractive or expensive. The Community page lets you see a range of Narratives in one place, from more bullish views that use higher 2029 earnings, margins and a P/E closer to the top analyst target of US$135 to more cautious views that lean toward the lower earnings estimates, slimmer margins and a fair value nearer US$92, with each Narrative updating automatically as new earnings, news or guidance is added.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.